New Option for the Treatment of IBS with Constipation is on the Horizon
Dynogen Pharmaceuticals, Inc. announced the start of an early phase of clinical research of their new medicine which promotes the motility of the gastrointestinal tract. The name of this new medicine is DDP733 (pumosetrag). In this new trial, the medicine is used in a randomized, double-blind, placebo-controlled fashion. This means that neither patients nor doctors who are involved in patient care are aware whether the patient is taking the active medicine or the placebo. This medicine can be a potential agent that can fill the vacuum generated in the market for the treatment of IBS with constipation after withdrawal of Zelnorm from the market due to safety issues. Medical News Today.